A new treatment for arrhythmia
Nature Medicine
March 30, 2009
A drug currently available in the clinic could be used to treat patients with an inherited form of cardiac arrhythmia, according to a study published this week in Nature Medicine.
CPVT―a specific type of ventricular tachycardia―is a potentially lethal form of arrhythmia. It is commonly linked to mutations in cardiac calcium channels known as ryanodine receptors. Pharmacological interventions against CPVT are often ineffective, but Bj?rn Knollmann and his colleagues have now found that flecainide―a drug already approved to treat other arrhythmias by acting on sodium channels―prevents disease in a mouse model of CPVT by a new mechanism: the direct inhibition of calcium release mediated by cardiac ryanodine receptors.
Flecainide also prevented CPVT in two patients who had not responded to conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy against this condition.
doi: 10.1038/nm.1942
Research highlights
-
Dec 4
Archaeology: Palaeolithic sea voyage to Japanese islands beyond the horizonScientific Reports
-
Dec 3
Ageing: Cellular rejuvenation restores vision in miceNature
-
Dec 1
Neurodegenerative disease: Two blood molecules may predict Alzheimer’s disease developmentNature Aging
-
Nov 27
Archaeology: Neanderthal thumbs better adapted to holding tools with handlesScientific Reports
-
Nov 26
Evolution: Ancient bird sticks its big beak into the evolutionary recordNature
-
Nov 26
Metabolism: Link between SARS-CoV-2 infection and cholesterol hints at COVID-19 treatment possibilitiesNature Metabolism
